Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 2026 entries
View as:

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues

Phase: N/A Priority: Normal
NCT ID: NCT01794234 Org: User:
Start: 08/31/12 End: 09/30/13 Due: 09/30/14

An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

Phase: N/A Priority: Normal
NCT ID: NCT01344889 Org: User:
Start: 10/31/09 End: 06/30/13 Due: 06/30/14

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Phase: N/A Priority: Normal
NCT ID: NCT05503264 Org: User:
Start: 09/27/22 End: 12/07/28 Due: 12/07/29

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Phase: N/A Priority: Normal
NCT ID: NCT04586023 Org: User:
Start: 03/24/21 End: 07/09/27 Due: 07/09/28

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01664533 Org: User:
Start: 09/30/11 End: 08/31/13 Due: 08/31/14

A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

Phase: N/A Priority: Normal
NCT ID: NCT03589105 Org: User:
Start: 08/06/18 End: 02/15/21 Due: 02/15/22

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Phase: N/A Priority: Normal
NCT ID: NCT01790217 Org: User:
Start: 07/31/12 End: 08/31/13 Due: 08/31/14

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00937560 Org: User:
Start: 06/25/09 End: 07/01/13 Due: 07/01/14

A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)

Phase: N/A Priority: Normal
NCT ID: NCT02010216 Org: User:
Start: 03/31/10 End: 07/31/10 Due: 07/31/11

An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01220934 Org: User:
Start: 04/16/10 End: 06/01/16 Due: 06/01/17

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Phase: N/A Priority: Normal
NCT ID: NCT03444870 Org: User:
Start: 06/06/18 End: 02/17/23 Due: 02/17/24

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00077610 Org: User:
Start: 02/29/04 End: 08/31/05 Due: 08/31/06

A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03155009 Org: User:
Start: 07/10/17 End: 09/26/19 Due: 09/26/20

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02616224 Org: User:
Start: 09/30/16 End: 12/31/25 Due: 12/31/26

A Single-Center Study of RO5508887 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01664143 Org: User:
Start: 07/31/12 End: 09/30/12 Due: 09/30/13

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03491150 Org: User:
Start: 04/11/18 End: 05/31/19 Due: 05/31/20

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01572038 Org: User:
Start: 06/01/12 End: 09/20/19 Due: 09/20/20

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Phase: N/A Priority: Normal
NCT ID: NCT01715818 Org: User:
Start: 12/31/12 End: 11/30/13 Due: 11/30/14

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase: N/A Priority: Normal
NCT ID: NCT03869190 Org: User:
Start: 06/01/19 End: 05/21/26 Due: 05/21/27

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Phase: N/A Priority: Normal
NCT ID: NCT04551352 Org: User:
Start: 10/28/20 End: 07/28/22 Due: 07/28/23

A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration

Phase: N/A Priority: Normal
NCT ID: NCT02194166 Org: User:
Start: 07/18/14 End: 07/12/18 Due: 07/12/19

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Phase: N/A Priority: Normal
NCT ID: NCT04524871 Org: User:
Start: 11/01/20 End: 12/31/26 Due: 12/31/27

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Phase: N/A Priority: Normal
NCT ID: NCT00442702 Org: User:
Start: 09/30/07 End: 08/31/10 Due: 08/31/11

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01174563 Org: User:
Start: 05/23/11 End: 12/20/16 Due: 12/20/17

A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00773188 Org: User:
Start: 12/31/08 End: 10/31/10 Due: 10/31/11